end,filed,form,Name,Ticker,CIK,Currency,AccountsPayableAndOtherAccruedLiabilitiesCurrent,AccountsPayableCurrent,AccretionAmortizationOfDiscountsAndPremiumsInvestments,AccruedProfessionalFeesCurrent,AccumulatedOtherComprehensiveIncomeLossNetOfTax,AdditionalPaidInCapital,AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,AllocatedShareBasedCompensationExpense,AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Assets,AssetsCurrent,AssetsFairValueDisclosure,CashAndCashEquivalentsAtCarryingValue,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect,CashEquivalentsAtCarryingValue,CommonStockParOrStatedValuePerShare,CommonStockSharesAuthorized,CommonStockSharesIssued,CommonStockSharesOutstanding,CommonStockValue,ComprehensiveIncomeNetOfTax,ConversionOfStockSharesConverted1,DeferredCosts,Depreciation,EarningsPerShareBasicAndDiluted,EmployeeRelatedLiabilitiesCurrent,EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions,FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings,FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues,FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements,FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue,GeneralAndAdministrativeExpense,GrantsReceivableCurrent,IncreaseDecreaseInAccountsPayable,IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities,IncreaseDecreaseInOtherOperatingAssets,IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets,InterestExpense,InterestIncomeDebtSecuritiesAvailableForSaleOperating,InvestmentIncomeInterest,Liabilities,LiabilitiesAndStockholdersEquity,LiabilitiesFairValueDisclosure,MarketableSecuritiesCurrent,MarketableSecuritiesNoncurrent,NetCashProvidedByUsedInFinancingActivities,NetCashProvidedByUsedInInvestingActivities,NetCashProvidedByUsedInOperatingActivities,NetIncomeLoss,NonoperatingIncomeExpense,OperatingExpenses,OperatingIncomeLoss,OtherAccruedLiabilitiesCurrent,OtherAssetsNoncurrent,OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax,OtherNonoperatingIncomeExpense,PaymentsToAcquireMarketableSecurities,PaymentsToAcquireProductiveAssets,PreferredStockParOrStatedValuePerShare,PreferredStockSharesAuthorized,PreferredStockSharesIssued,PreferredStockSharesOutstanding,PrepaidExpenseAndOtherAssetsCurrent,PrepaidInsurance,ProceedsFromIssuanceOfCommonStock,ProceedsFromIssuanceOfConvertiblePreferredStock,ProceedsFromStockOptionsExercised,PropertyPlantAndEquipmentNet,ReclassificationsOfTemporaryToPermanentEquity,ResearchAndDevelopmentExpense,RetainedEarningsAccumulatedDeficit,ShareBasedCompensation,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice,SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue,StockholdersEquity,StockIssuedDuringPeriodSharesPeriodIncreaseDecrease,StockIssuedDuringPeriodSharesStockOptionsExercised,StockIssuedDuringPeriodValueNewIssues,StockIssuedDuringPeriodValueStockOptionsExercised,TemporaryEquityCarryingAmountAttributableToParent,TemporaryEquityLiquidationPreference,TemporaryEquitySharesAuthorized,TemporaryEquitySharesIssued,TemporaryEquitySharesOutstanding,UnrecognizedTaxBenefits,UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense,WeightedAverageNumberOfShareOutstandingBasicAndDiluted,AociBeforeTaxAttributableToParent,DeferredTaxAssetsGross,DeferredTaxAssetsNet,DeferredTaxAssetsOperatingLossCarryforwards,DeferredTaxAssetsTaxCreditCarryforwardsResearch,DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost,DeferredTaxAssetsValuationAllowance,EffectiveIncomeTaxRateContinuingOperations,EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate,EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance,EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate,EffectiveIncomeTaxRateReconciliationNondeductibleExpense,EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent,EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes,EffectiveIncomeTaxRateReconciliationTaxCreditsResearch,IncomeTaxExpenseBenefit,IncomeTaxesPaidNet,InterestIncomeExpenseNonoperatingNet,InterestPaidNet,OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax,OtherNoncashExpense,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2021-06-30,2021-08-16,10-Q,"Acumen Pharmaceuticals, Inc.",ABOS,CIK0001576885,USD,1611000.0,2907000.0,,506000.0,,9241000.0,127000.0,127000.0,,72943000.0,70572000.0,36766000.0,68812000.0,,36800000.0,0.0001,50500000.0,556570.0,556570.0,,,,2352000.0,,-141.93,600000.0,,,,,0.0,1187000.0,109000.0,,,,,,,4000.0,4518000.0,72943000.0,,,,,,,-61358000.0,-57917000.0,3441000.0,-3441000.0,52000.0,13000.0,,19000.0,,,,,,,1651000.0,,,,,6000.0,,2254000.0,-115320000.0,,,,,,,,,,,,-106079000.0,,,,,174504000.0,94280000.0,42066830.0,28232672.0,28232672.0,0.0,,432325.0,,,,,,,,,,,,,,,,,,,,,,,,
2021-09-30,2021-11-15,10-Q,"Acumen Pharmaceuticals, Inc.",ABOS,CIK0001576885,USD,1107000.0,382000.0,,0.0,-28000.0,352606000.0,304000.0,304000.0,,234849000.0,204913000.0,228872000.0,135802000.0,,134800000.0,0.0001,300000000.0,40470323.0,40470323.0,4000.0,-3930000.0,,,,-0.1,797000.0,3100000.0,,,,0.0,2135000.0,109000.0,,,,,23000.0,,37000.0,1489000.0,234849000.0,,64162000.0,29910000.0,,,,-3902000.0,33000.0,3935000.0,-3935000.0,119000.0,13000.0,-28000.0,19000.0,,,0.0001,10000000.0,0.0,0.0,4840000.0,2299000.0,,,,13000.0,174504000.0,1800000.0,-119222000.0,,,51591000.0,3662365.0,1.92,14034000.0,958709.0,1.38,,,,233360000.0,,,168559000.0,2000.0,,,,,,0.0,,38266593.0,,,,,,,,,,,,,,,,,,,,,,,,
